Karen K.  Mcginnis net worth and biography

Karen Mcginnis Biography and Net Worth

Director of Absci
Ms. McGinnis has served as a member of our board of directors since August 2020. Ms. McGinnis also serves as an Independent Director of Alphatec Holdings, Inc. since June 2019 and of BioSplice Therapeutics, Inc. since March 2021. She was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement on April 2, 2021. Ms. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017, the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from  2000 through 2001. From 1997 to 2000, she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as its Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor’s degree in Accounting from the University of Oklahoma in 1989.

What is Karen K. Mcginnis' net worth?

The estimated net worth of Karen K. Mcginnis is at least $39,750.00 as of July 26th, 2021. Ms. Mcginnis owns 15,000 shares of Absci stock worth more than $39,750 as of November 21st. This net worth approximation does not reflect any other assets that Ms. Mcginnis may own. Learn More about Karen K. Mcginnis' net worth.

How do I contact Karen K. Mcginnis?

The corporate mailing address for Ms. Mcginnis and other Absci executives is , , . Absci can also be reached via phone at 360-949-1041 and via email at [email protected]. Learn More on Karen K. Mcginnis' contact information.

Has Karen K. Mcginnis been buying or selling shares of Absci?

Karen K. Mcginnis has not been actively trading shares of Absci during the past quarter. Most recently, on Monday, July 26th, Karen K. Mcginnis bought 15,000 shares of Absci stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $240,000.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company's stock, valued at $240,000. Learn More on Karen K. Mcginnis' trading history.

Who are Absci's active insiders?

Absci's insider roster includes Todd Bedrick (VP), Sarah Korman (General Counsel), Sean Mcclain (Insider), and Karen Mcginnis (Director). Learn More on Absci's active insiders.

Are insiders buying or selling shares of Absci?

In the last year, Absci insiders bought shares 1 times. They purchased a total of 222,222 shares worth more than $999,999.00. In the last year, insiders at the sold shares 2 times. They sold a total of 3,119,859 shares worth more than $13,738,897.82. The most recent insider tranaction occured on June, 13th when CFO Zachariah Jonasson sold 19,859 shares worth more than $98,897.82. Insiders at Absci own 9.8% of the company. Learn More about insider trades at Absci.

Information on this page was last updated on 6/13/2024.

Karen K. Mcginnis Insider Trading History at Absci

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/26/2021Buy15,000$16.00$240,000.0015,000View SEC Filing Icon  
See Full Table

Karen K. Mcginnis Buying and Selling Activity at Absci

This chart shows Karen K Mcginnis's buying and selling at Absci by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Absci Company Overview

Absci logo
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Read More

Today's Range

Now: $2.65
Low: $2.52
High: $2.70

50 Day Range

MA: $3.86
Low: $2.68
High: $4.32

2 Week Range

Now: $2.65
Low: $1.35
High: $6.72

Volume

769,269 shs

Average Volume

1,334,567 shs

Market Capitalization

$304.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18